Generic name:risankizumab-rzaa
Dosage form: subcutaneous injection
Drug class:Interleukin inhibitors
Medically reviewed by Drugs.com. Last updated on Jan 1, 2022.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
- Medication Guide
Indications and Usage for Skyrizi Injection
1.1 Plaque Psoriasis
SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
1.2 Psoriatic Arthritis
SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.
DOSAGE AND ADMINISTRATION
2.1 Plaque Psoriasis
The recommended dosage is 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
...